Research
Hormonal
Adult growth hormone deficiency (GHD) causes low bone turnover osteoporosis with a high risk of vertebral and nonvertebral fractures, but this low bone mass can be partially reversed by GH replacement therapy.
If you have been diagnosed with adult Growth Hormone Deficiency, GH replacement therapy is a valid medical intervention to help reverse low bone mass and reduce your risk of fractures. Consult an endocrinologist to determine if you are a candidate.
GoodSupportsHIGH confidence
Adult GH deficiency causes low bone turnover osteoporosis with high risk of vertebral and nonvertebral fractures, and the low bone mass can be partially reversed by GH replacement.
Why this rating
The paper is a comprehensive review citing numerous human clinical studies, animal models, and mechanistic data, though it is not a single randomized controlled trial.
Source
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Andrea Giustina et al. · Endocrine Reviews · 2008
DOI 10.1210/er.2007-0036
narrative_reviewCited 894×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- IGF-I enhances the differentiated function of mature osteoblasts and stimulates bone formation, but it does not directly direct the differentiation of undifferentiated stromal cells into osteoblasts.Strong
- Acromegaly, characterized by excess GH and IGF-I, leads to high bone turnover which can result in bone loss and vertebral fractures, particularly in patients with coexisting hypogonadism.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →